Bluejay Diagnostics Reports $6.8 Million Net Loss for Fiscal Year 2025, Faces Funding Challenges

Bluejay Diagnostics, Inc. reported a net loss of approximately $6.8 million for the fiscal year ending December 31, 2025, a decrease from a loss of about $7.7 million in 2024. The company has not generated any operating income since its inception, leading to an accumulated deficit of approximately $41.5 million as of the end of 2025. Total operating expenses for the year were approximately $6.95 million, down from $7.17 million in the previous year, primarily due to reduced research and development costs. The company’s cash and cash equivalents stood at approximately $5.2 million, with current liabilities of about $1.1 million, indicating a need for additional funding to sustain operations through 2026.

In terms of strategic developments, Bluejay is focused on advancing its Symphony platform, which is designed for rapid diagnostic testing in critical care settings, particularly for sepsis. The company is currently conducting the SYMON-II pivotal clinical trial, having enrolled approximately 583 patients out of a target of 750. The trial aims to validate the predictive performance of interleukin-6 (IL-6) levels in ICU patients for 28-day all-cause mortality. Bluejay plans to submit a 510(k) regulatory application to the FDA in 2027, contingent on successful trial outcomes and the resolution of manufacturing challenges related to its Symphony cartridges.

Operationally, Bluejay has reduced its workforce to six full-time employees as part of cost-saving measures, which may impact its ability to execute its business plan effectively. The company has also engaged Sanyoseiko, a contract manufacturing organization, to assist with the production of its Symphony cartridges, which are critical for the clinical trials and eventual commercialization of its products. The company’s reliance on external manufacturing and the need to establish a compliant manufacturing site by October 2026 are significant operational risks.

Looking ahead, Bluejay anticipates needing to raise at least $20 million by the end of the 2027 fiscal year to support its operations and regulatory strategy. The company has faced significant declines in its stock price since its IPO in November 2021, falling over 99.9%, which raises concerns about its ability to secure necessary funding. The filing indicates that failure to raise additional capital could lead to a liquidity crisis, potentially forcing the company to consider liquidation. The outlook remains uncertain as the company navigates regulatory hurdles and seeks to establish a market presence for its Symphony platform.